Rainbow FY26 net profit rises 15.3% to ₹2,815 million
Rainbow Children's Medicare Limited reported a 15.3% increase in consolidated net profit to ₹2,815.44 million for FY26, driven by a 12.4% rise in revenue to ₹17,030.77 million. EBITDA for the year grew 11.1% to ₹5,442 million with a margin of 32.0%. The board recommended a final dividend of ₹3.5 per share and re-appointed key directors. Operational metrics showed robust growth with capacity beds increasing 23% and outpatient consultations rising 12%.
*this image is generated using AI for illustrative purposes only.
[Rainbow Children's Medicare Limited](rainbow childrens medicare) has reported a 15.3% increase in consolidated net profit to ₹2,815.44 million for the financial year ended March 31, 2026, compared to ₹2,442.27 million in the previous year. Revenue from operations for the year rose 12.4% to ₹17,030.77 million from ₹15,158.66 million in FY25. The board of directors, in its meeting held on May 23, 2026, approved the audited standalone and consolidated financial results and recommended a final dividend of ₹3.5 per equity share. The company’s strong performance was driven by healthy momentum across operating metrics, including outpatient footfalls, inpatient discharges, and deliveries, alongside the successful commissioning of new facilities in Bengaluru.
Financial Performance
The company’s profitability improved alongside revenue growth. For the full year, total income reached ₹17,468.65 million, while total expenses stood at ₹13,870.97 million. Profit before tax for the year was ₹3,582.29 million. On a standalone basis, net profit for FY26 was ₹2,500.16 million, with revenue from operations reaching ₹15,456.60 million. EBITDA for the year rose 11.1% to ₹5,442 million, with an EBITDA margin of 32.0%.
The following table summarizes the key consolidated financial figures for the full year:
| Key Financial Figures (Consolidated) | Year Ended 31 March 2026 (₹ in Million) | Year Ended 31 March 2025 (₹ in Million) |
|---|---|---|
| Revenue from operations | 17,030.77 | 15,158.66 |
| Total income | 17,468.65 | 15,668.74 |
| Total expenses | 13,870.97 | 12,368.73 |
| Profit before tax | 3,582.29 | 3,300.01 |
| Profit after tax | 2,815.44 | 2,442.27 |
| Earnings per share (Basic) | 27.41 | 23.97 |
Q4 Performance
In the quarter ended March 31, 2026, consolidated net profit stood at ₹782.18 million, a 38.3% increase from ₹565.53 million in the same quarter of the previous year. Revenue from operations reached ₹4,599.01 million, compared to ₹3,701.07 million year-on-year. EBITDA for the quarter rose 26.1% to ₹1,447 million, with the EBITDA margin expanding to 31.5% from 31.0%. On a standalone basis, net profit for the quarter was ₹593.05 million on revenue of ₹4,080.64 million.
| Q4 Key Metrics | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Consolidated Revenue | ₹4,599.01 million | ₹3,701.07 million |
| Consolidated Net Profit | ₹782.18 million | ₹565.53 million |
| EBITDA | ₹1,447 million | ₹1,147 million |
| EBITDA Margin | 31.5% | 31.0% |
| Standalone Revenue | ₹4,080.64 million | — |
| Standalone Net Profit | ₹593.05 million | — |
Operational Highlights
The company maintained robust operational metrics during the year. Capacity beds increased 23% to 2,375, while operational beds grew 10% to 1,677. Occupancy for the year stood at 46.26%. Inpatient discharges rose 6% to 104,514, and outpatient consultations increased 12% to 15,98,970. Deliveries for the year reached 19,228. The Average Revenue Per Occupied Bed (ARPOB) improved 11% to ₹60,141, while the Average Length of Stay (ALOS) decreased to 2.71 days from 2.85 days in the previous year.
Dividend and Appointments
The board has recommended a final dividend of ₹3.5 per equity share, representing 35% on a face value of ₹10 per share for FY26. The total dividend payout aggregates to ₹355.46 million. The record date for determining eligibility has been fixed as July 21, 2026, and the payment is subject to shareholder approval at the 28th Annual General Meeting scheduled for July 29, 2026.
The board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director and Dr. Dinesh Kumar Chirla as Whole Time Director for a period of five years from August 11, 2026. Additionally, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms of five years each. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY27.
Investor Conference Call
Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the audio recording of the conference call held on May 25, 2026, with investors and analysts to discuss the financial and operational performance for Q4 and FY26 is now available on the company's website.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE961O01016/765b96f7-e995-470a-8cee-a3fbf38a46af.pdf
Historical Stock Returns for Rainbow Childrens Medicare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.43% | +9.77% | +8.84% | +11.08% | +0.82% | +226.70% |
What are the company's capital expenditure plans for FY27 to further expand capacity given the 23% increase in beds this year?
How does Rainbow Children's Medicare plan to sustain the current occupancy levels as the new Bengaluru facilities ramp up?
Will the company pursue further geographic expansion into new regions or focus on deepening presence in existing markets?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
